Analysis of Teva's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
Description
INTRODUCTION
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
HIGHLIGHTS
Teva has one launched biosimilar product: Tevagrastim (filgrastim), which had sales in Europe of $113m in 2011. The company's portfolio also contains two candidates that are awaiting registration - Neutroval (another filgrastim product) and XM17 (follitropin alfa), and three others that are in Phase III trials.
YOUR KEY QUESTIONS ANSWERED
See how aggressive M&A strategy has helped Teva enter the biosimilars arena
See how Teva will use its expertise with filgrastim biosimilars in the development of pegfilgrastim drugs
Table of Contents
Table of Contents
ABOUT THIS REPORT
Chapter structure
Strategic insight
Product analysis
Operating performance
Company introduction
Data sourcing
Analyst consensus
PharmaVitae Explorer database
EXECUTIVE SUMMARY
Teva biosimilars overview
Teva biosimilars infrastructure
STRATEGIC INSIGHT
Teva biosimilars SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Aggressive M&A strategy has helped Teva enter the biosimilars arena
Biopharmaceuticals represent a vital long-term growth opportunity for Teva
Teva will use its expertise with filgrastim biosimilars in the development of pegfilgrastim drugs
KEY PRODUCTS
Overview
Teva biosimilar portfolio
Tevagrastim/Ratiograstim and other filgrastim/pegfilgrastim products
Overview
Filgrastim market sizing
Key competitors
Teva biosimilar development
Clinical trials
XM17 (follitropin alfa)
Overview
Follitropin alfa market sizing
Key competitors
Teva biosimilar development
Clinical trials
TL011
Overview
Rituximab market sizing
Key competitors
Teva biosimilar development
Clinical trials
CORPORATE STRUCTURE
Background
Key corporate developments
Company structure
M&A history
Deals and alliances
APPENDIX
References
Datamonitor reports
Exchange rates
TABLES
Table: Teva - manufacturing and development metrics
Table: Teva - biosimilar portfolio
Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011-16
Table: Pipeline and marketed biosimilar filgrastim drugs
Table: Pipeline and marketed biosimilar pegfilgrastim drugs
Table: Teva biosimilar filgrastim clinical trials
Table: Forecasted follitropin alfa and follitropin beta sales ($m), 2011-16
Table: Pipeline and marketed biosimilar follitropin drugs
